Chief Editor Louis Garguilo at Outsourced Pharma asks “Are there strategic and tactical differences for [Large or Small Molecule] programs when outsourcing to CMOs?”
In the small molecule report (SMR), 70% of biopharma companies that use “preferred provider lists” responded that 1 to 5 CMOs make up that list; 20% said it was between 6 and 10 CMOs. Similarly, for the large molecule report (LMR), it was 84% percent for the 1-to-5 group, and 6% for the second.
Read more at Outsourced Pharma, and learn more about the reports used for the comparison: Small Molecule API Contract Manufacturer Quality Benchmarking (3rd Edition) and Biologic API Contract Manufacturer Quality Benchmarking (3rd Edition)
